Will antibodies raised against E. coli expressed cytokines recognise the Symansis human expressed cytokine?
Symansis’ cytokines are different from our competitor’s because the cytokines are expressed from human cells. This means that the cytokines have human post-translational modifications, such as glycosylation. It is possible that the antibody-binding sites may be masked by glycoproteins. Glycosylation may also facilitate protein folding into a more stable state, internalising antibody-binding sites (for antibodies derived against E. coli expressed cytokines). recombinant expression of human cytokines from NSO, CHO or insect cells (e.g. Sf21 cells) also facilitates glycosylation, but these expression systems may add glycan structures that are different when compared with the naturally occurring cytokine. It is anticipated that Symansis’ human expressed cytokines will behave differently to cytokines expressed using different expression systems such as E. coli or CHO. The exact difference observed would depend upon whether the antibody is monoclonal or polyclonal, and the epitope that the a
